Navigation Links
6th ESOU Meeting
Date:12/16/2008

The 6th Meeting of the European Society of Oncological Urology (ESOU) will be held in Istanbul, Turkey, from 16 to 18 January 2009, with organisers presenting the latest updates on treatment strategies to onco-urology specialists.

With the fast-changing developments in onco-urological treatment strategies, the ESOU aims to provide urologists, gynaecologists, oncologists, scientists and researchers the opportunity to explore the various options that will enable cancer specialists to identify optimal treatment approaches.

"The ESOU is and intends to remain - one of the most important platforms of scientific information exchange among experts as well as professionals interested in the field. It will continue to serve as a key opinion leader and promote the dissemination of high-quality uro-oncological scientific information, in order to increase the quality of medical service," said ESOU Chairman Prof. Vincent Ravery (Paris, France).

The most common malignancies such as prostate cancer (PCa), renal cell carcinoma and bladder cancer were the focus of last year's meeting in Berlin. Apart from these conditions, testis cancer will be another highlight of the forthcoming meeting in Istanbul.

Prof. Levent Trkeri (Istanbul, Turkey), ESOU board member and local organiser said: "On Friday, 16 January, an interesting pro-contra debate is organised entitled 'Should hormones (adjuvant/neo-adjuvant) be dedicated to radiotherapy and abandoned in patients to be treated with surgery?' Furthermore, the lecture by Prof. Theo de Reijke of the European Organisation on the Research and Treatment of Cancer-Genitourinary Group (Update on the recent data retrieved from EORTC GU group studies) deserves attention."

The introduction of targeted therapies, which will be discussed during the sessions on renal cell carcinoma, meant a revolution in the field of oncology in general. These therapies appear to evolve into the mainstay of medical treatment of malignancies of the urogenital tract and are likely to convert the disease from a progressive and lethal one into a chronic, controllable process in many cases.


'/>"/>

Contact: Lindy Brouwer
l.brouwer@uroweb.org
31-263-890-680
European Association of Urology
Source:Eurekalert

Related biology news :

1. Society for General Microbiology 161st Meeting, University of Edinburgh
2. Planetary geoscience, paleontology, and more at GSA Annual Meeting in Denver next month
3. Colony collapse disorder symposium added to ESA Annual Meeting
4. Meeting real-world climate information needs of business, government
5. Food and environmental sustainability focus of ASA-CSSA-SSSA Annual Meetings
6. NAS Biodiversity and Extinction Meeting Dec. 7-8
7. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
8. New studies on schizophrenia, depression, trauma and autism highlight annual meeting
9. Roger Kornberg to present lecture at the Joint Biophysical Society/IUPAB Meeting
10. Media advisory -- 2008 Ocean Sciences Meeting
11. ASNTR 15th anniversary meeting to be held May 1-3 in Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/6/2017)... DENVER , Feb. 6, 2017 ... national security are driving border authorities to continue ... Acuity reports there are 2143 Automated Border Control ... Kiosks currently deployed at more than 163 ports ... between 2013 to 2016 achieving a combined CAGR ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
(Date:2/1/2017)... Massachusetts , February 1, 2017 IDTechEx ... events on emerging technology, announces the availability of a new report, ... Continue Reading ... ... in industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  Champions Oncology, Inc. ... the development and sale of advanced technology solutions and ... drugs, today announced the addition of new cohorts of ... These new models will expand Champions, product line in ... and neck cancer, AML, and non-small cell lung cancer ...
(Date:2/16/2017)... NEW YORK , Feb. 16, 2017 ... $7M Series B financing, adding an additional $3M from ... by Mesa Verde Venture Partners and other strategic partners ... directed towards further accelerating commercial adoption of their flagship ... test and expanding the Paradigm cancer registry. ...
(Date:2/15/2017)... , 15. Februar 2017  Trianni, Inc. ... Biotech, Inc. (Janssen) eine Lizenzvereinbarung über die Verwendung ... Klasse führenden Plattform für die Entdeckung monoklonaler Antikörper. ... ihr neuartiges chimäres Gensegmentdesign aus, das Janssen ... humanen Antikörpern bietet und das für die schelle ...
(Date:2/15/2017)... 15, 2017 Windtree Therapeutics, Inc. (Nasdaq: ... aerosolized KL4 surfactant therapies for respiratory diseases, will host ... at 8:00 AM EST on Thursday, February 16, 2017 ... program, the recently announced closing of a $10.5 million ... To participate in the live call and take ...
Breaking Biology Technology: